Faktor-VIII-Konzentrate

• LITERATUR

• 1 Brinkhous K. M., Hemker H. C. (Eds.). Handbook of Hemophilia. Part I and II. Excerpta Medica, Amsterdam 1975
• 2 Menaché D., Surgenor D. M., Anderson H. D. (Eds.) Hemophilia and Hemo-stasis. Alan R. Liss, New York 1981
• 3 Zimmerman T. S., Meyer D. Structure and function of factor VIII/von Willebrand factor. In Bloom A. L., Thomas D. P. (Eds.) Haemostasis and Thrombosis. Churchill Livingstone; Edinburgh: 1981: 111-123
• 4 Kingdon H. S., Hassell T. M. Hemophilic dog model for evaluating hemostatic efficacy of plasma protein fractions. Thromb. Haemost. 1981; 46: 217.
• 5 Griggs T. R., Potter J., McClanahan S. B., Webster W. P., Brinkhous K. M. Macro-molecular factor VIII complex: functional and structural heterogeneity observed in von Willebrand swine with transfusion. Proc. Natl. Acad. Sci. USA 1977; 74: 759-763
• 6 Thelin G. M., Wagner R. H. Sedimentation of plasma antihemophilic factor. Arch. Biochem. Biophys. 1961; 95: 70-76
• 7 Owen W. G., Wagner R. H. Antihemophilic factor. A new method of purification. Thromb. Res. 1972; 1: 71-87
• 8 Vehar G. A., Davie E. W. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 1980; 19: 401-410
• 9 Penick G. D., Brinkhous K. M. Relative stability of plasma antihemophilic factor (AHF) under different conditions of storage. Am. J. Med. Sci. 1956; 232: 434-441
• 10 Sola B., Avner P., Sultan Y., Jeanneau C., Maisonneuve P. Monoclonal antibodies against human factor VIII molecule neutralize antihemophilic factor and ristocetin cofactor activities. Proc. Natl. Acad. Sci. USA 1982; 79: 183-187
• 11 Seegers W. H., McCoy L. E., Groben H. D., Sakuragawa N., Agrawal B. B. L. Purification and some properties of auto-prothrombin II-A: an anticoagulant perhaps also related to fibrinolysis. Thromb. Res. 1972; 1: 443-460
• 12 Lamb M. A., Reisner H. M., Cooper H. A., Wagner R. H. The multimeric distribution of factor Vlll-related antigen studied by an improved crossed-immunoelectrophoresis technique. J. Lab. Clin. Med. 1981; 98: 751-763
• 13 Sarji K. E., Stratton R. D., Wagner R. H., Brinkhous K. M. Nature of von Willebrand factor: a new assay and a specific inhibitor. Proc. Natl. Acad. Sci. USA 1974; 71: 2937-2941
• 14 Stratton R. D., Wagner R. H., Webster W. P., Brinkhous K. M. Antibody nature of circulating inhibitor of plasma von Willebrand factor. Proc. Natl. Acad. Sci. USA 1975; 72: 4167-4171
• 15 Furlan M., Perret B. A., Beck E. A. Studies on factor VIII-related protein IV. Interaction of galactose-specific lectins with human factor VIII/von Willebrand factor. Biochim. Biophys. Acta 1980; 623: 402-411
• 16 Geratz J. D., Tidwell R. R., Brinkhous K. M., Mohammad S. F., Dann O., Loewe H. Specific inhibition of platelet agglutination and aggregation by aromatic amidino compounds. Thromb. Haemost. 1978; 39: 411-425
• 17 Vukovich T., Koller E., Doleschel W. The influence of thrombin on the platelet-aggregating activity of human factor VIII. A study with insolubilized thrombin. Thromb. Haemost. 1979; 42: 832-837
• 18 Martin S. E., Marder V. J., Francis C. W., Loftus L. S., Barlow G. H. Enzymatic degradation of the factor-VIII-von-Wille-brand protein: a unique tryptic fragment with ristocetin cofactor activity. Blood 1980; 55: 848-858
• 19 Switzer M. E., McKee P. A. Studies on human antihemophilic factor: evidence for a covalently linked subunit structure. J. Clin. Invest. 1976; 57: 925-937
• 20 Triantaphyllopoulos D. C, McGarry B. J. Cryoprecipitates and blood-groups. Lancet 1979; 2: 203.
• 21 Pepper M. D., Learoyd P. A., Rajah S. M. Plasma factor VIII. variables affecting stability under standard blood bank conditions and correlation with recovery in concentrates. Transfusion 1978; 18: 756-760
• 22 McLeod B. C., Sassetti R. J., Cole E. R., Pierce M. I. Factor VIII collection by pheresis. Lancet 1980; 2: 671-673
• 23 Wagner R. H., McLester W. D., Smith M., Brinkhous K. M. Purification of antihemophilic factor (Factor VIII) by amino acid precipitation. Thromb. Diath. Haemorrh. 1964; 11: 64-74
• 24 Newman J., Johnson A. J., Karpat-kin M. H., Puszkin S. Methods for the production of clinically effective intermediate- and highpurity factor-VIII concentrates. Br. J. Haematol. 1971; 21: 1-20
• 25 Kang E. P. An improved thaw-siphon method for the cryoprecipitate preparation. Vox Sang. 1980; 38: 172-177
• 26 Pool J. G., Shannon A. E. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system: assay in vitro and in vivo. N. Engl. J. Med. 1965; 273: 1443-1447
• 27 Mason E. C. Thaw-siphon technique for production of cryoprecipitate concentrate of factor VIII. Lancet 1978; 2: 15-17
• 28 Toolis F., McKay G., Prowse C. V. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations. Thromb. Haemost. 1980; 43: 25-27
• 29 Ness P. M., Perkins H. A. Fibrinogen in cryoprecipitate and its relationship to factor VIII (AHF) levels. Transfusion 1980; 20: 93-96
• 30 Jones P., Martin-Villar J., De Vreker R., Taub R. (Eds.) Management of the hemophilias. Scand. J. Haematol. 1980 24. Suppl.35
• 31 Aronson D. L. Factor VIII (antihemophilic globulin). Semin. Thromb. Hemost. 1979; 6: 12-27
• 32 Allain J. P., Verroust F., Soulier J. P. In vitro and in vivo characterization of factor VIII preparations. Vox Sang. 1980; 38: 68-80
• 33 Blatt P. M., Brinkhous K. M., Gulp H. R., Krauss J. S., Roberts H. R. Antihemophilic factor concentrate therapy in von Wille-brand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. J.A.M. A. 1976; 236: 2770-2772
• 34 Lee H., Chavin S. I., Blewitt R. E., Austen D. E. G. Large scale purification and characterization of porcine factor VIII for clinical use. Thromb. Haemost. 1977; 38: 349.
• 35 Johnson A. J., MacDonald V. E., Semar M., Fields J. E., Schuck J., Lewis C., Brind J. Plasma protein fractionation using solid-phase polyelectrolytes. In Curling J. M. (Ed.) Methods of Plasma Protein Fractionation Academic Press; London: 1980: 129-147
• 36 Costello W. P., Middletown S. M., Malia R. G. A new clinical preparation of high-purity porcine factor VIII :C concentrate. Thromb. Haemost. 1981; 46: 15.
• 37 Brinkhous K. M. Assay of platelet aggregating von Willebrand factor. In CRC Handbook Series in Clinical Laboratory Science. Section I: Hematology. Vol. III Schmidt R. M. CRC Press; Boca Raton: 1980: 141-147 (Ed.).
• 38 Langdell R. D., Wagner R. H., Brinkhous K. M. Effect of antihemophilic factor on one-stage clotting tests. J. Lab. Clin. Med. 1953; 41: 637-647
• 39 Nye S. W., Graham J. B., Brinkhous K. M. The partial thromboplastin time as a screening test for the detection of latent bleeders. Am. J. Med. Sci. 1962; 243: 279-287
• 40 Brinkhous K. M., Dombrose F. A. Partial thromboplastin time. In CRC Handbook Series in Clinical Laboratory Science. Section I: Hematology. Vol. III Schmidt R. M. CRC Press; Boca Raton: 1980: 221-246 (Ed.).
• 41 Biggs R., Macfarlane R. G. Human blood coagulation. Thomas, Springfield 1957
• 42 Biggs R., Douglas A. S. The thromboplastin generation test. J. Clin. Pathol. 6 1953; 23-29
• 43 Seghatchian M. J., Kemball-Cook G., Barrowcliffe T. W. Absorption of factor VIII by aluminium hydroxide. Haemostasis 1979; 8: 106-116
• 44 Hoyer L. W. The factor VIII complex: structure and function. In Menache D., Surgenor D. M., Anderson H. D. (Eds.) Hemophilia and Hemostasis; Alan R. Liss; New York: 1981: 1-26
• 45 Howard M. A., Firkin B. G. Ristocetin-a new tool in the investigation of platelet aggregation. Thromb. Diath. Haemorrh. 1971; 26: 362-369
• 46 Read M. S., Shermer R. W., Brinkhous K. M. Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor. Proc. Natl. Acad. Sci. USA 1978; 75: 4514-4518
• 47 Griggs T. R., Cooper H. A., Webster W. P., Wagner R. H., Brinkhous K. M. Plasma aggregating factor (bovine) for human platelets: a marker for study of antihemophilic and von Willebrand factors. Proc. Natl. Acad. Sci. USA 1973; 70: 2814-2818
• 48 Weiss H. J., Rogers J., Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J. Clin. Invest. 1973; 52: 2697-2707
• 49 Brinkhous K. M., Read M. S. Preservation of platelet receptors for platelet aggregating factor/von Willebrand factor by air drying. frezing, or lyophilization: new stable platelet preparations for von Willebrand factor assays. Thromb. Res. 1978; 13: 591-597
• 50 Brinkhous K. M., Barnes D. S., Potter J. Y., Read M. S. Von Willebrand syndrome induced by a Bothrops venom factor: bioassay for venom coagglutinin. Proc. Natl. Acad. Sci. USA 1981; 78: 3230-3234
• 51 Brinkhous K. M., Read M. S. Use of venom coagglutinin and lyophilized platelets in testing for platelet-aggregating von Willebrand factor. Blood 1980; 55: 517-520
• 52 Miller C. H., Graham J. B., Goldin L. R., Elston R. C. Genetics of classic von Willebrand's disease. I. Phenotypic variation within families. Blood 1979; 54: 117-136
• 53 Weiss A. E., Webster W. P., Strike L. E., Brinkhous K. M. Survival of transfused factor VIII in hemophilic patients treated with epsilon aminocaproic acid. Transfusion 1976; 16: 209-214
• 54 Brinkhous K. M., Carney C. N., Shermer R. W. Use of high-potency antihemophilic concentrates in prophylaxis. Thromb. Diath. Haemorrh. Suppl. 1971; 43: 139-147
• 55 Aronstam A., Wassef M., Choudhury D. P., Turk P. M. Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A. Lancet 1980; 1: 169-171
• 56 Brinkhous K. M. Hemophilia. Bull. N. ć. Acad. Med. 1954; 30: 325-342
• 57 McMillan C. W., Webster W. P., Roberts H. R., Blythe W. B. Continuous intravenous infusion of factor VIII in classic haemophilia. Brit. J. Haematol. 1970; 18: 659-667
• 58 Aronstam A., McLellan D. S., Turk P. Transfusion requirements of adolescents with severe hemophilia A. J. Clin. Pathol. 32: 927-930 1979;
• 59 Brinkhous K. M., Swanton M. C., Webster W. P., Roberts H. R. Hemophilic arthropathy: transfusion therapy in its amelioration - canine and human studies. In Van-derfield I. R. (Ed.) Proc. Symp. Hemophilia. Sydney, Australia The Hemophilia Society of N.S.W.; 1966: 18-21
• 60 Rabiner S. F., Telfer M. C. Home transfusion for patients with hemophilia A. N. Engl. J. Med. 1970; 283: 1011-1015
• 61 Franklin F. I. Trends in the treatment of hemophilia A: patient-administered clotting factor program. Thromb. Diath. Haemorrh. Suppl. 1971; 43: 467-470
• 62 Levine P. H., Britten A. F. H. Supervised patient-management of hemophilia. Ann. Intern. Med. 1973; 78: 195-201
• 63 Kasper C. K. Self-infusion treatment program. In Brinkhous K. M., Hemker H. C. (Eds.) Handbook of Hemophilia Excerpta Medica; Amsterdam: 1975: 597-603
• 64 Rabiner S. F. Home infusion treatment program. In Brinkhous K. M., Hemker H. C. (Eds.) Handbook of Hemophilia Excerpta Medica; Amsterdam: 1975: 591-596
• 65 Van Eys J. Home transfusion for hemophilia. In Hilgartner M. W. (Ed.) Hemophilia in Children Publishing Sciences Group; Littleton (Mass.): 1976: 185-200
• 66 Evensen S. A., Thaule R., Groan K. Self-therapy for haemophilia in Norway. Acta Med. Scand. 1979; 205: 395-399
• 67 Deutsch E. Die Hemmkörperhämophilie. Springer, Wien 1950
• 68 Brinkhous K. M., Shanbrom E., Roberts H. R., Webster W. P., Fekete L., Wagner R. H. A new high-potency glycine-pre-cipitated antihemophilic factor (AHF) concentrate. J.A.M.A. 1968; 205: 613-617
• 69 Allain J. P., Roberts H. R. Treatment of acute bleeding episodes in hemophilic patients with specific factor VIII antibodies. In Brinkhous K. M., Hemker H. C. (Eds.) Handbook of Hemophilia Excerpta Medica; Amsterdam: 1975: 659-671
• 70 Lechner K. Report of the Working Party on Acquired Inhibitors to Coagulation Fac tors. 26th Annual Meeting, International Committee on Thrombosis and Haemos-tasis, Boston 1980
• 71 Roberts H. R., Knowles M. R., Jones T. L., McMillan C. W. Use of factor VIII concen trates in the management of patients with factor VIII inhibitors. In Brinkhous K. M. (Ed.) Hemophilia and New Hemorrhagic States University of North Carolina Press; Chapel Hill: 1970: 152-163
• 72 Blatt P. M., White G. C., McMillan C. W., Roberts H. R. Treatment of anti-factor VIII antibodies. Thromb. Haemost. 1977; 38: 514-523
• 73 Biggs R. (ed.) The Treatment of Haemophilia A and B and von Willebrand's Disease. Blackwell; Oxford: 1978
• 74 Brackmann H. H., Etzel R., Hofmann P., Egli H. The successful treatment of acquired inhibitors against factor VIII. Thromb. Haemost. 1977; 38: 369.
• 75 Bennett E., Dormandy K. Pool's cryo-precipitate and exhausted plasma in the treatment of von Willebrand's disease and factor-IX deficiency. Lancet 1966; 2: 731-732
• 76 Sultan Y. Rationale for the treatment of von Willebrand's disease. In Menache D., Surgenor D. M., Anderson H. D. (Eds.) Hemophilia and Hemostasis. Alan R. Liss; New York: 1981
• 77 Brinkhous K. M., Culp H. R. Quantitation of von Willebrand factor and an antibody inhibitor. Thromb. Res. 8, Suppl. II: 1976; 125-132
• 78 Bloom A. L., Peake I. R., Furlong R. A., Davies B. L. High potency factor VIII concentrate: more effective than cryoprecipi-tate in a patient with von Willebrand's disease and inhibitor. Thromb. Res. 1979; 16: 847-852
• 79 Ness P. M., Perkins H. A. Cryoprecipitate as a reliable source of fibrinogen replacement. J.A.M.A. 1979; 241: 1690-1691
• 80 Snyder E. L., Mosher D. F., Hezzey A., Golenkowsky G. Effect of blood transfusion on in vivo levels of plasma fibronectin. J. Lab. Clin. Med. 1981; 98: 336-341
• 81 Fratantoni J. C., Aronson D. L. (Eds.). Unsolved Therapeutic Problems in Hemophilia. DHEW Publication No. (NIH) 1977; 77-1089
• 82 Brinkhous K. M., Roberts H. R., Weiss A. E. Prevalence of inhibitors in hemophilia A and B. Thromb. Diath. Haemorrh. Suppl. 1972; 51: 315-320
• 83 Shapiro S. S., Hultin M. Acquired inhibitors to the blood coagulation factors. Sem. Thromb. Hemost. 1975; 1: 336-385
• 84 Sultan Y., Maisonneuve P. Incidence des inhibiteurs du facteur VIII dans la population des hemophiles francais. Nouv. Rev. fr. Hemat. 1977; 18: 671-673
• 85 Frommel D., Allain J. P., Saint-Paul E., Bosser C., Noël B., Mannucci P. M., Pan-nicucci F., Blombäck M., Prou-Wartelle O., Muller J. Y. HLA antigens and factor VIII antibody in classic hemophilia. Thromb. Haemost. 1981; 46: 687-689
• 86 Bloom A. L. Current status and trends in the treatment of hemophilic patients with inhibitors. In Menache D., Surgenor D. M., Anderson H. D. (Eds.) Hemophilia and Hemostasis Alan R. Liss; New York: 1981: 123-138
• 87 Vermylen J. Complications of infusion therapy - reaction to infusion. In Brinkhous K. M., Hemker H. C. (Eds.) Handbook of Hemophilia Excerpta Medica; Amsterdam: 1975: 605-611
• 88 Rosati L. A., Barnes B., Oberman H. A., Penner J. A. Hemolytic anemia due to anti-A in concentrated antihemophilic factor preparations. Transfusion 1970; 10: 139-141
• 89 Orringer E. P., Koury M. J., Blatt P. M., Roberts H. R. Hemolysis caused by factor VIII concentrates. Arch. Intern. Med. 1976; 136: 1018-1020
• 90 Shapiro S. Antibody responses in the hemophiliac. In Fratantoni J. C, Aronson D. L. (Eds.) Unsolved Problems in Hemophilia 103-111. DHEW Publication No.; (NIH): 1977: 77-1089
• 91 Prager D., Djerassi I., Eyster M. E., Gill F. M., Kajani N. K., Lewis J. H., Lusch S., Shapiro S. S. Pennsylvania state-wide hemophilia program: summary of immediate reactions with the use of factor VIII and factor IX concentrate. Blood 1979; 53: 1012-1013
• 92 Eyster M. E., Nau M. E. Particulate material in antihemophilic factor (AHF) concentrates. Transfusion 1978; 18: 576-581
• 93 Boese E. C, Tantum K. R., Eyster M. E. Pulmonary function abnormalities after infusion of antihemophilic factor (AHF) concentrates. Am. J. Med. 1979; 67: 474-476
• 94 Grignani G., Gamba G., Ascani E. »In vivo« platelet aggregates after replacement therapy in patients with hemophilia A. Thromb. Haemost. 1979; 42: 813-814
• 95 Holmberg L., Ljung R. Purification of F. VIII:C by antigen-antibody chromatography. Thromb. Res. 1978; 12: 667-675
• 96 Baxter Travenol signs pact for biotechnology work on clotting agent. Wall Street Journal, April 2. 1982